eccogene glp 1 Elecoglipron Shows Positive Results in Phase 1b Trial in China Eccogene Announces Positive Topline Results

Given that obesity is a chronic and relapsing disease, it is important to understand the effectiveness of different strategies to maintain WL: TRIUMPH-6 (NCT06859268) will assess changes in bodyweight at 116 weeks in individuals with obesity who have completed 80 weeks of retatrutide, comparing continued treatment at high or low doses of retatrutide versus switching to placebo for the last 36 weeks

Credit: Instagram/Shilpa Shetty Coconut oil has multiple anti-inflammatory and antibacterial properties

CuCl 2 and Cu(OAc) 2 were only found to be cytotoxic at 5800 M and cell viability decreased significantly after 48 h treatment at 580 M

GLP-1 receptor agonists are a popular class of medications used to help manage type 2 diabetes and, more recently, support weight loss